Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Development of Human Laboratory Study Model of Cocaine Relapse Prevention. - 1

This study is ongoing, but not recruiting participants.
Information provided by:
National Institute on Drug Abuse (NIDA) Identifier:
First received: June 18, 2002
Last updated: January 10, 2017
Last verified: September 2004
The purpose of this study is to assess the development of human laboratory study model of cocaine relapse prevention.

Condition Intervention Phase
Cocaine-Related Disorders
Procedure: Cocaine (IV)
Phase 1

Study Type: Interventional
Study Design: Intervention Model: Parallel Assignment
Masking: Double-Blind
Primary Purpose: Treatment
Official Title: Development of Human Laboratory Study Model of Cocaine Relapse Prevention

Resource links provided by NLM:

Further study details as provided by National Institute on Drug Abuse (NIDA):

Primary Outcome Measures:
  • Cocaine craving
  • Cocaine related high

Estimated Enrollment: 32
Study Start Date: May 2002
Estimated Study Completion Date: August 2003
Detailed Description:
The primary objective of this study will be to develop experimental procedures and parameters demonstrating arousal and craving responses to cocaine-related environmental cues as a model for future testing of the relapse prevention medication treatment of cocaine addiction.

Ages Eligible for Study:   18 Years to 55 Years   (Adult)
Genders Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Cocaine dependent, non treatment seeking individuals

Exclusion Criteria:

Please contact site directly for details.

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00040066

United States, California
UCLA Integrated Substance Abuse Program
Los Angeles, California, United States, 90024
United States, Texas
University of Texas Health Science Center
San Antonio, Texas, United States, 78284
Sponsors and Collaborators
National Institute on Drug Abuse (NIDA)
Principal Investigator: John Roache, Ph.D. National Institute on Drug Abuse (NIDA)
  More Information Identifier: NCT00040066     History of Changes
Other Study ID Numbers: NIDA-CTO-0013-1 
Study First Received: June 18, 2002
Last Updated: January 10, 2017
Health Authority: United States: Food and Drug Administration

Additional relevant MeSH terms:
Cocaine-Related Disorders
Substance-Related Disorders
Chemically-Induced Disorders
Mental Disorders
Anesthetics, Local
Central Nervous System Depressants
Physiological Effects of Drugs
Sensory System Agents
Peripheral Nervous System Agents
Vasoconstrictor Agents
Dopamine Uptake Inhibitors
Neurotransmitter Uptake Inhibitors
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Dopamine Agents
Neurotransmitter Agents processed this record on January 18, 2017